The presented results support highly significant improvements (i.e. up to 30% reduction in CV hazard ratios) for SGLT2 inhibitors in patients with HFrEF (independently of the potentially co‐existing T2DM) and illustrate a moderate benefit for HFpEF patients.
1
—
—